StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Unbiased

<< Previous

Bullboard Posts

Next >>

Comment by MSmitty2020on Dec 03, 2020 7:48pm

112 Views

Post# 32034035

RE:RE:Unbiased

I agree and thanks for the comment

quote=capebretongirl]

MSmitty2020 wrote:
Investor ... been here for close to a year and must say there are two major camps ... extremely positive and simply negative ... I have to assume there is motivation for both... I simply look at facts ... stage is generating cash that is a fact ... excellent opportunity from Covid ... SP movement is not following for two key reasons ... The Covid revenue has no defined life... contracts are not of any dollar value ... not that it is bad to have 50 potential customers, however without some long term contracts or significant prospects i.e. Aristotle this SP is limited ... what is needed is significant commitment in the future which is Aristotle ... without this truly there is a ceiling ... I want $4.00 like everyone else but no defined future revenue stream will not lead to this massive run that is often talked about ... IMO

Absolutely correct and my thoughts for a long time. This is a cancer detection company currently benefitting from a short term revenue generating phenomenon - all of which will be good for the company but only on a short term basis. Clarus recognizes this in its sp forecast as it sees Aristotle being rolled out next year at the tail end of covid and continuing the revenue stream after it. The come for covid - stay for cancer is a perfectly timed business venture SO LONG as Aristotle does hit the market by mid 2021. A proglonged delay of Aristotle would change Clarus' forecast big time for this reason.

[/quote]

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid